Suggested Remit: To appraise the clinical and cost effectiveness of semaglutide within its marketing authorisation for treating type 2 diabetes.
Status Awaiting development
Decision None selected
Process STA 2018
ID number 1450

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
29 April 2019 Following the scoping exercise this topic was not referred to NICE for a Technology Appraisal. It was agreed the topic would be incorporated in clinical guideline update (NICE guideline 28). The block scoping report containing this topic is published here; (Batch 64)
22 November 2018 - 20 December 2018 Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators

For further information on our processes and methods, please see our CHTE processes and methods manual